Azura Ophthalmics

Ophthalmic Keratolytics

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in December 2013 by Yair Alster, Azura Ophthalmics operates with 11–50 employees. The company has raised $37.2M across four funding rounds from four investors, with OrbiMed participating as a lead investor. In October 2022, Azura Ophthalmics expanded its intellectual property portfolio to include 12 U.S. and European patents.

Business overview

Azura Ophthalmics is a Health Tech & Life Sciences company focused on developing a new therapeutic class of ophthalmic keratolytics. The company utilizes a deep understanding of ocular surface diseases and drug development to treat underserved ophthalmic conditions. Its core product, AZR-MD-001, is in a robust clinical-stage program targeting meibomian gland dysfunction and contact lens discomfort. Azura Ophthalmics also develops novel chemical entities with multi-modal mechanisms of action for ocular surface diseases, operating within the Pharmaceuticals, Biotechnology, and Drugs Discovery & Development sectors globally.

Strategic signal

In September 2022, Azura Ophthalmics secured a grant to evaluate AZR-MD-001 for improved vision quality related to contact lens discomfort. This grant signals continued external validation of the company's lead therapeutic candidate and its potential to address significant unmet needs in ophthalmic care, reinforcing investor confidence in its clinical development pipeline and market potential.

Company Intelligence Q&A

When was Azura Ophthalmics founded?
Azura Ophthalmics was founded in December 2013.
Who is the founder of Azura Ophthalmics?
Yair Alster is the founder of Azura Ophthalmics.
What is the total capital raised by Azura Ophthalmics?
Azura Ophthalmics has raised a total of $37.2 million.
Which investors participated in Azura Ophthalmics' October 2020 funding round?
In October 2020, Azura Ophthalmics received funding from OrbiMed and Ganot Capital.
What significant intellectual property milestone did Azura Ophthalmics achieve recently?
In October 2022, Azura Ophthalmics expanded its intellectual property portfolio to include 12 U.S. and European patents.

External links